-
Mashup Score: 5
This study explores the potential benefits of neoadjuvant chemotherapy in borderline resectable (BR) pancreatic adenocarcinoma. Despite neoadjuvant treatment (NAT) increasingly being utilised, uncertainty remains as to the optimal approach.
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Treatment and follow-up (FU) care procedures for gastrointestinal stromal tumors (GISTs) impose great challenges on patients and could potentially affect their health-related quality of life (HRQoL). The aims of our study were to (i) assess HRQoL among patients with GIST in different treatment phases and settings and to compare this with the HRQoL of an age- and sex-matched normative population, (ii) determine the occurrence of disease- and treatment-specific symptoms, and (iii) investigate which sociodemographic and clinical characteristics and symptoms were associated with HRQoL.
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet-
👩⚕️ How is health-related quality of life impacted by therapy in #GIST? #HRQoL Check out @myESMO ESMO Real World Data and Digital Oncology study: https://t.co/KJfdR83T6J 1/2
-
-
Mashup Score: 0
Patients with metastatic colorectal cancer (mCRC) with RAS- or BRAF-mutant tumors do not benefit from epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) therapy. Among patients with RAS/BRAF wild-type (WT) tumors, a substantial portion still do not benefit from EGFR mAb treatment. Using real-world clinicogenomic data, we investigated the impact of primary and acquired genomic resistance alterations upon treatment outcomes and determined the prevalence of alterations before and after EGFR mAb treatment.
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet-
📢 Clinico-genomics #RWD to investigate primary and acquired resistance to EGFR mAb in #colorectal cancer (mCRC). Read this comprehensive analysis in ESMO Real World Data and Digital Oncology, from @flatironhealth @FoundationATCG https://t.co/0He8TyXjkb @myESMO 1/2
-
-
Mashup Score: 1Evaluation of machine learning methods for the retrospective detection of ovarian cancer recurrences from chemotherapy data - 9 day(s) ago
Cancer recurrences are poorly recorded within electronic health records around the world. This hinders research into the efficacy of cancer treatments. Currently, the retrospective identification of recurrence/progression diagnosis dates is achieved by staff who manually review patients’ health records. This is expensive, time-consuming, and inefficient. Machine Learning models may expedite the review of health records and facilitate the assessment of alternative cancer therapies.
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet-
•The models identify both initial and subsequent cancer recurrences. •Models can use chemotherapy alone to identify recurrence dates. •Survival informed from model-identified dates matches chart review survival. 📘 https://t.co/ATD524nqpP @myESMO 2/2 https://t.co/8X7sbXgEcl
-
-
Mashup Score: 2Equitable access to oncology clinical trials: harnessing technology to reduce geographic disparities - 4 month(s) ago
Clinical trials (CTs) play a crucial role in advancing new oncology therapies and their eventual integration into cancer care. However, despite the increasing number of available CTs, <5% of patients with cancer are included.1 The biggest challenge in getting patients with cancer to participate in CTs is the lack of available trials at the hospital where the patient is being treated, due to the heterogeneous distribution of CTs.2 Other key factors that significantly influence patient recruitment for CTs and still require substantial attention are significant social disparities and certain structural issues within health care systems, such as incompatibilities between public and private systems within the same country.
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet-
Technology can help oncologists: ✔️ Search clinical trials and directly refer patients ✔️ Reduce disparities in access to innovative therapies Check out the recent Perspective publication at ESMO RWD and Digital Oncology ➡️ https://t.co/R6iA7slWtz @TrialingHealth https://t.co/9mJAAXnJ7m
-
-
Mashup Score: 0
In the past year, ChatGPT has surged in popularity as a tool for education and research due to its remarkable capabilities.1,2 Leveraging artificial intelligence (AI), ChatGPT showcases a broad skill set, crafting original content, addressing queries, and assembling coherent sentences from inputs.3,4 It additionally refines itself through self-correction.5
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet-
(2/2) Read today in ESMO Real World Data and Digital Oncology https://t.co/da58NYHS9p @curijoey
-
-
Mashup Score: 0ESMO Real-World Data and Digital Oncology: a journal to realize that health systems can help provide better cancer care. - 7 month(s) ago
Real-world data (RWD) and digital health are a new field of science that will support many aspects of clinical practice. They are vehicles that can return value to society in an unprecedented manner in the form of generalizable observational research, population health management, learning healthcare systems, direct-to-patient mobile applications, among others. RWD can be the basis for many interrogations, such as describing underrepresented populations in clinical trials, reporting new phenomena and effectiveness of medical interventions in uncontrolled environments, exposing gaps in patient care, identifying accessibility issues of cancer drugs, supporting public policy and regulatory decisions.
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet-
Our first articles for the new @myesmo journal ESMO Real World Data and Digital Oncology have published today. @rdienstmann shares his ambitions for this exciting new journal https://t.co/OBRzcObTHO https://t.co/SH7KOVuqL9
-
-
Mashup Score: 0ESMO Real-World Data and Digital Oncology: a journal to realize that health systems can help provide better cancer care. - 7 month(s) ago
Real-world data (RWD) and digital health are a new field of science that will support many aspects of clinical practice. They are vehicles that can return value to society in an unprecedented manner in the form of generalizable observational research, population health management, learning healthcare systems, direct-to-patient mobile applications, among others. RWD can be the basis for many interrogations, such as describing underrepresented populations in clinical trials, reporting new phenomena and effectiveness of medical interventions in uncontrolled environments, exposing gaps in patient care, identifying accessibility issues of cancer drugs, supporting public policy and regulatory decisions.
Source: www.esmorwd.orgCategories: General Medicine News, Onc News and JournalsTweet-
Our first articles for the new @myesmo journal ESMO Real World Data and Digital Oncology have published today. @rdienstmann shares his ambitions for this exciting new journal https://t.co/OBRzcObTHO https://t.co/SH7KOVuqL9
-
-
Mashup Score: 0Home Page: ESMO Real World Data and Digital Oncology - 7 month(s) ago
ESMO Real-World Data and Digital Oncology is the European Society for Medical Oncology’s latest peer-reviewed open access journal. It is dedicated to publishing high-quality data science and educational content on the transformation of oncology care with real-world evidence and digital technologies that physicians can trust and understand. The journal will publish innovative research that provides actionable insights from real-world data sources and digital devices, such as generalizable observational
Source: www.esmorwd.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
➡️Guidelines for RWD reporting ➡️ChatGPT in medical research ➡️ESMO RWD & Digital Oncology vision and mission https://t.co/o8SQzPwre7 DO NOT MISS THE FIRST ONLINE PAPERS❗️ https://t.co/oY3FevCg3e
-
-
Mashup Score: 1Home Page: ESMO Real World Data and Digital Oncology - 7 month(s) ago
ESMO Real-World Data and Digital Oncology is the European Society for Medical Oncology’s latest peer-reviewed open access journal. It is dedicated to publishing high-quality data science and educational content on the transformation of oncology care with real-world evidence and digital technologies that physicians can trust and understand. The journal will publish innovative research that provides actionable insights from real-world data sources and digital devices, such as generalizable observational
Source: www.esmorwd.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
This work represents a milestone for #RWD studies in #oncology ! ➡️ Access ESMO RWD and Digital Oncology content here: https://t.co/o8SQzPwre7 @OncologyAdvance @myESMO https://t.co/qqe8b2SKB0
-
📢 #RWD in borderline resectable pancreatic cancer Emerging evidence in ESMO Real World Data and Digital Oncology: https://t.co/ZlgF0Y9pBr @myESMO 🔍 Study findings - Neoadjuvant FOLFIRINOX associated with improved survival versus upfront surgery. https://t.co/fkCDQmhCw6